INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD)
© 2026 IJNRD | Volume 11, Issue 11, November 2026 | ISSN: 2456-4184 | IJNRD.ORG

Alcohol-Associated Liver Disease: Pathophysiological Spectrum, Novel Diagnostics, Emerging Therapeutics, and Future Perspectives

Mr. Gaurang D Padelkar*, Mr. Dnyaneshwar S Vyavhare, Dr. Somnath K Thorat, Dr. Mahesh R Sherkar

Department of Pharmacy, BR Harne College of Pharmacy, Vangani

ABSTRACT

Alcohol-associated liver disease (ALD) represents the leading cause of preventable chronic liver morbidity and mortality globally, with an escalating epidemiological footprint across the Indian subcontinent. Transitioning from the older stigmatizing nomenclature of alcoholic liver disease, contemporary hepatology classifies the condition along a dynamic histopathological continuum encompassing alcohol-associated steatosis, steatohepatitis, progressive fibrosis, compensated and decompensated cirrhosis, and acute-on-chronic liver failure (ACLF). Chronic ethanol metabolism generates acetaldehyde, reactive oxygen species, and lipid peroxidation adducts while disrupting intestinal epithelial tight junctions, thereby driving gut dysbiosis and translocation of pathogen-associated molecular patterns into the portal circulation. While sustained alcohol abstinence and targeted nutritional rehabilitation remain foundational pillars of care, standard pharmacological options for severe alcohol-associated hepatitis—principally glucocorticoids—confer only modest short-term survival gains and carry substantial infectious risks. Recent translational breakthroughs led by Indian and international consortia have introduced transformative therapeutic strategies, including healthy-donor fecal microbiota transplantation, granulocyte colony-stimulating factor mobilization, interleukin-22 agonists, epigenetic modulators such as larsucosterol, and therapeutic plasma exchange. Furthermore, emerging evidence demonstrates that prolonged abstinence enables hepatic recompensation even in advanced decompensated states. This review synthesizes the clinical staging, molecular mechanisms, diagnostic innovations, and emerging therapeutic landscape of ALD, integrating pivotal clinical data generated between 2022 and 2026 to outline future precision-medicine paradigms.

1. INTRODUCTION AND EPIDEMIOLOGICAL BURDEN

Alcohol-associated liver disease (ALD) constitutes one of the most pressing public health challenges in modern hepatology, accounting for a substantial proportion of cirrhosis-related mortality and liver transplantation listings worldwide (1,3,14). In India, rapid urbanization, shifting sociocultural norms, and earlier initiation of hazardous drinking have transformed ALD into the predominant etiology of chronic liver disease and acute-on-chronic liver failure (ACLF) presenting to tertiary care centers (1,15,16). Epidemiological cohorts from Northern, Western, and Southern India consistently demonstrate that alcohol accounts for over 45% to 80% of hospitalized cirrhosis cases, frequently affecting men in their most economically productive decades between 35 and 50 years of age (13,15-17).

Beyond direct clinical mortality, ALD imposes a severe socioeconomic burden on healthcare infrastructure and households (3). Markov probabilistic modeling evaluating the health and economic impact of ALD in urban Indian populations highlights substantial direct medical expenditures, catastrophic out-of-pocket healthcare spending, and massive losses in quality-adjusted life years (3). Moreover, the post-pandemic era has witnessed a sharp surge in severe alcohol-associated hepatitis (SAH) admissions and decompensated presentations, compounded by rising rates of concurrent metabolic risk factors such as central obesity and type

2 diabetes mellitus (14,18). Recognizing the dual metabolic and alcohol-induced drivers of hepatotoxicity, international consensus frameworks have refined disease taxonomy to better capture overlapping clinical phenotypes (1,4).

2. NOMENCLATURE EVOLUTION AND CLINICAL STAGES OF ALD

Modern hepatology has formally replaced pejorative terminology such as "alcoholic" with "alcohol-associated" or "alcohol-related" liver disease to reduce patient stigma and encourage early engagement with addiction medicine services (1,4,19). The clinical and histological progression of ALD follows a well-characterized spectrum, though patients frequently exhibit overlapping features rather than strictly linear transitions (1,20).

2.1 Alcohol-Associated Steatosis (AAS)

Alcohol-associated steatosis represents the earliest and most prevalent hepatic response to sustained ethanol intake, developing in over 90% of individuals consuming more than 40 to 60 grams of alcohol daily (1,20). Histologically, it is characterized by macrovesicular lipid droplet accumulation within centrilobular (zone 3) hepatocytes resulting from an elevate $NADH/NAD^+$ redox ratio, upregulation of sterol regulatory element-binding protein-1c (SREBP-1c), and inhibition of peroxisome proliferator-activated receptor-alpha (PPAR-α)-mediated fatty acid β-oxidation (1,6). Clinically, AAS is largely asymptomatic and entirely reversible within two to four weeks of complete alcohol cessation, though continued drinking drives progression toward necroinflammation (20).

2.2 Alcohol-Associated Steatohepatitis (ASH) and Fibrosis

In approximately 20% to 35% of heavy drinkers, simple steatosis evolves into alcohol-associated steatohepatitis (ASH), defined histologically by hepatocellular ballooning, neutrophilic lobular inflammation, apoptotic bodies, and intracytoplasmic eosinophilic aggregates termed Mallory-Denk bodies (1,20). Persistent necroinflammation activates quiescent hepatic stellate cells (HSCs) into collagen-producing myofibroblasts, generating a characteristic perivenular and pericellular "chicken-wire" fibrosis pattern that progressively bridges portal tracts and central veins (1,6,21).

2.3 Alcohol-Associated Hepatitis (AH) and Severe AH (SAH)

Alcohol-associated hepatitis is a distinct, acute clinical syndrome superimposed on underlying chronic liver injury, presenting with rapid-onset jaundice, malaise, tender hepatomegaly, fever, and leukocytosis following recent heavy alcohol consumption (1,7,14). Disease severity is stratified using Maddrey's Discriminant Function (mDF $\geq$ 32) or the Model for End-Stage Liver Disease (MELD $\geq$ 20), which identify severe alcohol-associated hepatitis (SAH)—a critical condition carrying a 28-day mortality rate of 20% to 40% (7,8,14).

2.4 Compensated and Decompensated Cirrhosis

Continued fibrogenesis culminates in micronodular cirrhosis, marked by architectural distortion, regenerative nodules, and intrahepatic vascular resistance (1,16). While compensated cirrhosis may remain clinically silent for years, rising portal venous pressure precipitates decompensation events including ascites, gastroesophageal variceal hemorrhage, overt hepatic encephalopathy (HE), spontaneous bacterial peritonitis (SBP), and hepatorenal syndrome (HRS) (16,20,22). Crucially, multicenter Indian clinical investigations demonstrate that sustained abstinence allows roughly 20% of patients with decompensated ALD cirrhosis to achieve formal Baveno VII recompensation, dramatically improving transplant-free survival (13).

2.5 Alcohol-Associated Acute-on-Chronic Liver Failure (ALD-ACLF)

When an acute hepatic insult—most commonly severe AH, bacterial sepsis, or variceal bleeding—triggers rapid hepatic decompensation alongside extrahepatic organ failures (renal, cerebral, coagulation, circulatory,

or respiratory), patients progress to ALD-ACLF (11,18,22). Indian and Asian-Pacific cohorts reveal that ALD-ACLF carries exceptionally high short-term mortality, which is further exacerbated by comorbid type 2 diabetes mellitus, systemic fungal or bacterial infections, and severe sarcopenia (18,22-24).



Disease Stage	Key Histological & Clinical Features	Diagnostic & Prognostic Tools	Reversibility & Natural History
Alcohol-Associated Steatosis (AAS)	Zone 3 macrovesicular steatosis (>5%); asymptomatic hepatomegaly	Ultrasonography, Controlled Attenuation Parameter (CAP), MRI-PDFF	Fully reversible within 2–4 weeks of complete abstinence (20,25)
Alcohol-Associated Steatohepatitis (ASH)	Hepatocyte ballooning, Mallory-Denk bodies, lobular neutrophils, pericellular fibrosis	Liver biopsy, FibroScan (VCTE), ELF score, FIB-4	Reversible with abstinence; 10%–20% per year progress to cirrhosis if drinking continues (1,20)
Severe Alcohol-Associated Hepatitis (SAH)	Acute jaundice (bilirubin >3 mg/dL), AST:ALT >1.5, coagulopathy, SIRS	mDF ≥ 32, MELD ≥ 20, Glasgow AH Score, Lille Score (Day 4/7)	High 28-day (20%–40%) and 90-day mortality; high infection susceptibility (7,8,14)
Compensated Cirrhosis	Diffuse regenerative nodules, fibrous septa, subclinical portal hypertension	Liver stiffness (>15–20 kPa), platelet count, HVPG (6–10 mmHg)	Stable if abstinent; ~5%–7% annual transition to decompensation with ongoing alcohol use (1,16)

Decompensated Cirrhosis & ACLF	Ascites, variceal bleed, HE, HRS, multi-organ failure	Child-Turcotte-Pugh (CTP), MELD-Na, CLIF-C ACLF, AARC score	Up to 20% achieve Baveno VII recompensation with prolonged abstinence; otherwise requires LT (13,18,22)

3. PATHOPHYSIOLOGICAL MECHANISMS: THE GUR-LIVER-IMMUNE AXIS

The pathogenesis of ALD involves a complex interplay between direct ethanol hepatotoxicity, mitochondrial oxidative stress, epigenetic reprogramming, and profound disruption of the gut–liver axis (2,5,6).

3.1 Ethanol Metabolism and Oxidative Stress

Hepatocytes metabolize ethanol primarily via cytosolic alcohol dehydrogenase (ADH) and microsomal cytochrome P450 2E1 (CYP2E1), generating acetaldehyde—a highly reactive electrophile that forms mutagenic DNA and protein adducts (1,6). Chronic alcohol exposure induces a tenfold upregulation of CYP2E1, which leaks electrons during catalytic cycling to generate abundant reactive oxygen species (ROS), including superoxide anions and hydrogen peroxide (6). Concurrently, ethanol depletes mitochondrial glutathione (GSH) and impairs endogenous antioxidant enzymes such as superoxide dismutase 1 (SOD1), triggering lipid peroxidation, endoplasmic reticulum stress, and regulated hepatocyte cell death via apoptosis, necroptosis, and pyroptosis (6,20).

3.2 Gut Dysbiosis and Intestinal Barrier Breakdown

A pivotal driver of disease progression from simple steatosis to SAH and ACLF is the breakdown of intestinal mucosal integrity (5,10,11). Ethanol and its luminal metabolite acetaldehyde directly degrade tight-junction proteins—specifically zonula occludens-1 (ZO-1) and occludin—while thinning the protective intestinal mucus layer (2,5). Simultaneously, chronic alcohol consumption induces severe taxonomic and functional gut dysbiosis characterized by the depletion of beneficial short-chain fatty acid (SCFA)-producing commensals (such as *Lachnospiraceae*, *Ruminococcaceae*, and *Roseburia*) and the expansion of pathogenic *Proteobacteria*, *Enterobacteriaceae*, and cytolysin-producing *Enterococcus faecalis* (5,10,11).

3.3 Innate Immune Hyperactivation and Impaired Regeneration

Increased intestinal permeability permits bacterial lipopolysaccharide (LPS) and fungal β-glucans to translocate into the portal venous system (5,9). Upon reaching the hepatic sinusoids, LPS binds to Toll-like receptor 4 (TLR4) and CD14 complexes on resident Kupffer cells, triggering MyD88-dependent nuclear factor-kappa B (NF-$_k$B) signaling and inflammasome assembly (2,6). This cascade unleashes a storm of pro-inflammatory cytokines—including tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and CXCL8—which recruit activated neutrophils into the hepatic parenchyma (2,8,14). Paradoxically, while innate immune pathways are hyperactivated, patients with SAH exhibit profound adaptive immune exhaustion, neutrophil bactericidal dysfunction, and epigenetic silencing of hepatocyte proliferation genes, leaving the liver unable to regenerate amidst overwhelming bacterial infection risk (8,12).

4. NOVEL DIAGNOSTIC BIOMAKERS, IMAGING, AND RISK STRATIFICATION

Accurate, non-invasive staging and early detection of alcohol misuse are essential to interrupt disease progression before irreversible cirrhosis develops (17,25).

4.1 Direct Alcohol Biomarkers and AUD Screening

Because self-reported alcohol intake is frequently underestimated due to stigma, objective direct ethanol biomarkers have been integrated into routine hepatology practice (1,19). Phosphatidylethanol (PEth) measured in whole blood detects moderate-to-heavy alcohol consumption over the preceding two to four weeks with

>90% sensitivity and specificity, remaining unaffected by liver disease severity (1,14). Urinary ethyl glucuronide (EtG) and ethyl sulfate (EtS) provide reliable detection within a 72-to-96-hour window, assisting clinicians in monitoring abstinence pre- and post-liver transplantation (1,19). Concurrent psychiatric screening using the Alcohol Use Disorders Identification Test (AUDIT) and Severity of Alcohol Dependence Questionnaire (SADQ) is indispensable, as Indian clinical studies reveal that nearly 100% of hospitalized ALD patients meet diagnostic criteria for alcohol dependence syndrome, with higher SADQ scores correlating directly with cirrhotic decompensation (17,19).

4.2 Non-Invasive Fibrosis Assessment and Proteomic Signatures

Vibration-controlled transient elastography (VCTE/FibroScan) accurately quantifies hepatic steatosis via Controlled Attenuation Parameter (CAP) and liver stiffness measurement (LSM) (25). However, active alcohol-associated steatohepatitis and elevated transaminases (>100 IU/L) can spuriously elevate LSM values, necessitating higher diagnostic cutoffs (>15–20 kPa) or repeat measurement after two weeks of abstinence (1,25). Serum composite panels, including the Enhanced Liver Fibrosis (ELF) test and Fibrosis-4 (FIB-4) index, offer reliable outpatient triage (1,14). Emerging translational studies from India have further identified novel non-invasive indicators, including platelet proteomic signatures via liquid chromatography–mass spectrometry, progressive declines in serum magnesium across advancing ALD stages, and elevated serum uric acid correlating strongly with Child-Turcotte-Pugh (CTP) severity (16,26,27).

4.3 Frailty, Sarcopenia, and Prognostic Scoring

Malnutrition and sarcopenia affect over 60% of patients with advanced ALD cirrhosis and independently predict hepatic encephalopathy, sepsis, and waitlist mortality (23,24). Prospective clinical cohorts from Northern India have validated simple bedside functional assessments—specifically handgrip strength (HGS) and gait speed (GS)—alongside the Liver Frailty Index (LFI), demonstrating strong correlation with computed tomography-derived skeletal muscle index (CT-SMI) and superior prognostic discrimination for 6-month hospitalization and mortality (23,24). In acute SAH, dynamic prognostic scoring utilizing the baseline MELD score combined with the Day-4 or Day-7 Lille model (<0.45 indicating corticosteroid responsiveness) remains the gold standard for guiding early therapeutic pivots (8,14).

5. CURRENT STANDARD OF CARE

Management of ALD requires a dual-track clinical approach addressing both underlying alcohol use disorder (AUD) and hepatic organ dysfunction (1,19).

5.1 Alcohol Abstinence and Integrated Addiction Pharmacotherapy

Complete and sustained alcohol abstinence is the single most powerful determinant of long-term survival across every stage of ALD, capable of reversing steatosis, halting fibrosis, and inducing clinical recompensation in decompensated cirrhosis (13,19,20). Multidisciplinary care models embedding addiction psychiatrists within hepatology clinics significantly reduce relapse rates (19). Because disulfiram carries risks of idiosyncratic hepatotoxicity and naltrexone undergoes hepatic metabolism, **acamprosate** (renally excreted) and off-label **baclofen** (a $GABA_B$ receptor agonist safe in advanced cirrhosis) represent the preferred anti-craving pharmacotherapies in patients with significant hepatic impairment, paired with motivational enhancement therapy and cognitive behavioral therapy (1,19).

5.2 Nutritional Rehabilitation

Protein-calorie malnutrition and micronutrient deficiencies (thiamine, folate, pyridoxine, zinc, vitamin D, and magnesium) are nearly universal in severe ALD (14,27). Current clinical guidelines refute historical protein restriction practices, recommending a daily caloric intake of 35–40 kcal/kg and protein intake of 1.2–1.5 g/kg body weight, supplemented with a late-evening complex carbohydrate/protein snack to prevent overnight

catabolic muscle breakdown (1,14). Enteral nasogastric feeding is indicated whenever oral intake falls below target thresholds (14).

5.3 Glucocorticoids in Severe Alcohol-Associated Hepatitis

For patients with SAH (mDF ≥ 32 or MELD ≥ 20) without active bacterial/fungal infection, gastrointestinal bleeding, or acute kidney injury, oral prednisolone (40 mg/day for 28 days) remains the guideline-endorsed first-line pharmacotherapy (1,8,14). While prednisolone improves 28-day survival by blunting hepatic macrophage activation, large trials and meta-analyses confirm no sustained survival advantage at 90 days or 1 year, largely due to high rates of steroid non-response (~30%–40%) and opportunistic bacterial or invasive fungal infections (7,8,12).

6. NOVEL AND EMERGING THERAPIES (2022-2026 EVIDENCE)

To overcome the ceiling effect and infectious hazards of corticosteroids, extensive translational research between 2022 and 2026 has pioneered targeted interventions directed at the gut microbiome, hepatic regeneration, epigenetic regulation, and extracorporeal detoxification (8-12).

Therapeutic Class	Specific Agent / Intervention	Primary Mechanism of Action	Key Clinical Evidence (2022–2026)	Current Development Status
Microbiome Modulation	Healthy-Donor Fecal Microbiota Transplantation (FMT)	Restores commensal SCFA-producing flora, repairs gut barrier, reduces endotoxemia	Indian RCTs (Pande et al., 2022; Sharma et al., 2022) showed superior 90-day survival (75% vs 56.6% with steroids) and fewer infections (10,11)	Phase II/III clinical trials; used in specialized centers (8,9)
Hepatic Regeneration	Granulocyte Colony-Stimulating Factor (G-CSF) + Prednisolone	Mobilizes $CD34^+$ bone marrow stem cells, enhances hepatocyte proliferation & neutrophil function	GPreAH RCT (Mishra et al., 2024/2025) demonstrated 88.1% 90-day survival with G-CSF + prednisolone vs 64.3% with steroids alone (8)	Phase II/III trials; widely studied in Asia/India (8,12)
Cytokine / Repair Agonists	Interleukin-22 (IL-22) Agonist (F-652)	Activates hepatic STAT3 signaling, promotes hepatocyte survival & antimicrobial peptides	Phase IIa open-label trial demonstrated 94.4% 42-day survival, marked MELD reduction, and favorable safety profile (7)	Advancing to randomized Phase IIb/III trials (7)

Epigenetic Modulators	Larsucosterol (DUR-928)	Sulfated oxysterol inhibiting DNA methyltransferases (DNMT1, DNMT3a/3b); anti-apoptotic	Phase IIb AHFIRM trial showed strong mortality reduction trends in US/global cohorts with excellent safety (7)	Phase III clinical development planned (7)
Extracorporeal Detoxification	Therapeutic Plasma Exchange (TPE) / Bioartificial Liver	Removes circulating DAMPs, cytokines, bile acids, and ammonia; bridges to recovery/LT	Clinical trials in India (NCT06355726) and ACLF cohorts show improved hemodynamics and transplant-free survival (9,12)	Active randomized clinical evaluation (9,12)
Anti-Oxidant & Nano-Therapeutics	Nano-formulated Superoxide Dismutase 1 (NanoSOD1) & Tributyrin	Scavenges mitochondrial ROS; restores histone acetylation & intestinal butyrate	Preclinical/translational studies (Gopal et al., 2025; Ghare et al., 2023) show marked attenuation of steatohepatitis (6,28)	Preclinical / Early translational stage (6,28)

6.1 Healthy-Donor Fecal Microbiota Transplantation (FMT)

Indian hepatology centers have spearheaded the clinical translation of healthy-donor fecal microbiota transplantation (FMT) for steroid-ineligible and steroid-eligible SAH and ALD-ACLF (9-11). In a landmark randomized controlled trial comparing daily nasoduodenal FMT against prednisolone in 120 SAH patients, Pande et al. demonstrated significantly superior 90-day survival in the FMT arm (75% vs. 56.6%, $p = 0.044$), accompanied by markedly lower rates of secondary infections (3.3% vs. 20%) and restoration of beneficial *Lachnospiraceae* and *Prevotella* taxa (10). Similarly, open-label controlled trials in ALD-ACLF confirmed that single-session jejunal FMT significantly improved 28-day (100% vs. 60%) and 90-day (53.8% vs. 25%) survival while reducing systemic IL-1β levels and resolving ascites and encephalopathy (11). Parallel investigations from Southern India further confirmed durable long-term reductions in alcohol relapse rates and hepatic decompensation following FMT compared to standard care or pentoxifylline (29,30).

6.2 Granulocyte Colony-Stimulating Factor (G-CSF) Combination Regimens

Granulocyte colony-stimulating factor (G-CSF) stimulates bone marrow mobilization of $CD34^+$ hematopoietic and mesenchymal stem cells into the injured liver, promoting parenchymal regeneration while reversing cirrhosis-associated neutrophil paralysis (8,12). In the pivotal GPreAH randomized controlled trial conducted at the Institute of Liver and Biliary Sciences (ILBS), New Delhi, Mishra et al. evaluated the combination of subcutaneous G-CSF plus prednisolone versus prednisolone monotherapy in steroid-eligible SAH (8). Combination therapy increased Day-7 Lille responsiveness to 92.9% (versus 71.4% with steroids alone) and dramatically improved 90-day transplant-free survival (88.1% vs. 64.3%, $p = 0.03$), while significantly reducing new-onset bacterial infections (19% vs. 35.7%), acute kidney injury, and hospital readmissions (8).

6.3 Interleukin-22 Agonists and Epigenetic Modulators (Larsucosterol)

Interleukin-22 (IL-22) is a hepatoprotective cytokine that binds exclusively to epithelial/hepatocyte IL-22R1 receptors without activating immune cells, thereby stimulating STAT3-mediated hepatocyte proliferation and anti-apoptotic Bcl-2 expression without exacerbating systemic inflammation (7). Clinical evaluation of recombinant human IL-22Fc (F-652) in moderate-to-severe AH demonstrated rapid reductions in MELD scores, decreased serum inflammatory markers, and a 42-day survival rate of 94.4% (7). Concurrently, epigenetic dysregulation—specifically hypermethylation of hepatocyte regenerative promoters—has emerged as a major therapeutic target (7). Larsucosterol (DUR-928), an endogenous sulfated oxysterol that inhibits DNA methyltransferases (DNMT1, DNMT3a, and DNMT3b), demonstrated clinically meaningful reductions in 90-day mortality and liver transplantation in Phase IIb trials, positioning epigenetic reprogramming as a frontline non-immunosuppressive therapy (7).

6.4 Therapeutic Plasma Exchange, Bovine Colostrum, and Targeted Nano-Antioxidants

Extracorporeal blood purification via therapeutic plasma exchange (TPE) removes circulating damage-associated molecular patterns (DAMPs), pro-inflammatory cytokines, bilirubin, and ammonia, restoring monocyte phagocytic function in severe ALD-ACLF (9,12). Ongoing Indian randomized trials are actively defining optimal TPE protocols to bridge critically ill SAH patients to spontaneous recovery or transplantation (9,12). Additionally, hyperimmune bovine colostrum—rich in anti-LPS immunoglobulins and lactoferrin—is undergoing Phase III evaluation in India to neutralize gut-derived endotoxemia (9). At the molecular frontier, nanoparticle-encapsulated superoxide dismutase 1 (NanoSOD1) and oral butyrate prodrugs (tributyrin) have demonstrated potent efficacy in neutralizing hepatic mitochondrial oxidative stress and restoring histone-H3 acetylation in experimental ALD models (6,28).

6.5 Early Liver Transplantation and Baveno VII Recompensation

For patients with severe AH unresponsive to medical therapy (Lille score > 0.45) or end-stage decompensated cirrhosis, early liver transplantation (LT) without the arbitrary historical "6-month sobriety rule" has become an established life-saving standard, yielding 1-year survival rates exceeding 85% when paired with rigorous psychosocial support and multidisciplinary addiction care (1,14). Simultaneously, landmark multicenter Indian data published in 2026 established that among patients with decompensated ALD cirrhosis who maintain strict abstinence, 20% achieve complete clinical and biochemical recompensation per Baveno VII criteria—defined as resolution of ascites and encephalopathy off diuretics/lactulose and absence of variceal bleeding for at least 12 months—resulting in over 92% transplant-free survival (13).

7. FUTURE PERSPECTIVES

The management of ALD over the next decade will shift from reactive treatment of end-stage decompensation toward precision, multi-omic risk stratification and dual-organ therapeutics (1,12,18).

1. Precision Microbiome and Bacteriophage Engineering: Moving beyond whole-stool FMT, next-generation microbiome therapeutics will deploy standardized, lyophilized live biotherapeutic consortia and targeted bacteriophages engineered to selectively eradicate cytolysin-producing *Enterococcus faecalis* without disrupting commensal flora (9,19).

2. Integrated MetALD and Metabolic-Targeted Therapies: With rising obesity and diabetes prevalence in India, the overlap syndrome of metabolic dysfunction and alcohol-associated liver disease (MetALD) requires dual-pathway pharmacotherapy (4,18). Repurposing glucagon-like peptide-1 (GLP-1) receptor agonists, fibroblast growth factor-21 (FGF21) analogs, and pan-PPAR agonists offers the dual promise of attenuating hepatic steatohepatitis while simultaneously curbing central neurobiological alcohol cravings (18,21).

3. AI-Driven Multi-Omic Prognostication: Integrating blood-based transcriptomics, circulating extracellular vesicle microRNAs, and machine-learning models with point-of-care elastography will enable clinicians to identify "rapid progressors" at primary care clinics and predict corticosteroid or FMT responsiveness prior to therapy initiation (12,26).

4. Public Health Policy and Early Screening Networks: In high-burden regions like India, embedding transient elastography and AUDIT screening into primary care and district hospital NCD (non-communicable disease) clinics, alongside strict alcohol taxation and public health education, will be vital to curb premature mortality (3,15,16).

8. CONCLUSION

Alcohol-associated liver disease remains a complex, multi-systemic disorder driven by the synergistic convergence of direct ethanol-induced oxidative hepatotoxicity, epigenetic silencing of hepatic regeneration, and gut-derived endotoxemia (2,6,7). While early stages of steatosis and steatohepatitis are fully reversible, progression to severe alcohol-associated hepatitis and acute-on-chronic liver failure carries devastating short-term mortality (8,14,20). Sustained alcohol abstinence supported by integrated addiction pharmacotherapy and aggressive nutritional rehabilitation constitutes the indispensable foundation of care across all disease stages (13,14,19). Crucially, the therapeutic landscape has expanded beyond the limitations of glucocorticoid monotherapy; robust clinical trial evidence generated between 2022 and 2026 validates healthy-donor fecal microbiota transplantation, G-CSF combination regimens, IL-22 agonists, and epigenetic modulators as transformative interventions that enhance survival without compounding infectious risks (7,8,10,11). Combining these targeted biological therapies with early non-invasive fibrosis screening and structured psychosocial support holds the key to achieving durable hepatic recompensation and reversing the global tide of ALD mortality (1,13,19).

REFERENCES

1. Shasthry SM, Sarin SK. Alcohol-Associated Liver Diseases: Spectrum, Nomenclature, and Definitions. Clin Liver Dis. 2024;28(4):621-631. doi:10.1016/j.cld.2024.06.003.
2. Nagarjuna D, Karthikeyan E. Alcohol-associated Liver Disease: A Review. Gastroenterol Endosc. 2025;3(1):1-12.
3. Ramalingam A, Pasupuleti SSR, Nagappa B, Sarin SK. Health and economic burden due to alcohol-associated liver diseases in the Union Territory of Delhi: A Markov probabilistic model approach. Indian J Gastroenterol. 2022;41(1):84-95. doi:10.1007/s12664-021-01221-4.
4. Jophlin LL, Singal AK, Bataller R, Wong RJ, Sauer BG, Terrault NA, et al. ACG Clinical Guideline: Alcohol-Associated Liver Disease. Am J Gastroenterol. 2024;119(1):30-54. doi:10.14309/ajg.0000000000002572.
5. Philips CA, Ahamed R, Rajesh S, Singh S, Tharakan A, Abduljaleel JK, et al. Clinical outcomes and gut microbiota analysis of severe alcohol-associated hepatitis patients undergoing healthy donor fecal transplant or pentoxifylline therapy: single-center experience from Kerala. Gastroenterol Rep (Oxf). 2022;10:goac074. doi:10.1093/gastro/goac074.
6. Gopal T, Kathiravan ADJ, Kabanov AV, Casey CA, Saraswathi V. The Pathophysiology of Alcohol-Associated Liver Disease: Focusing on Superoxide Dismutase 1 as a Therapeutic Target. Biology (Basel). 2025;14(10):1319. doi:10.3390/biology14101319.
7. Kumar R, Elangovan S, Asrani SK. Emerging therapeutic regimens as alternatives to glucocorticoids for severe alcohol-associated hepatitis: a comprehensive review. Clin Mol Hepatol. 2026;32(2):599-619. doi:10.3350/cmh.2025.1163.
8. Mishra AK, Shasthry SM, Vijayaraghavan R, Kumar G, Sarin SK. Granulocyte Colony-Stimulating Factor Improves Prednisolone Responsiveness and 90-Day Survival in Steroid-Eligible Severe Alcohol-

Associated Hepatitis: The GPreAH Study a Randomized Trial. Am J Gastroenterol. 2025;120(5):1087-1097. doi:10.14309/ajg.0000000000003038.
9. Wagh RS, Shasthry SM, Sarin SK. New Approaches to Alcohol-Associated Hepatitis. Clin Liver Dis. 2025;29(4):595-626. doi:10.1016/j.cld.2025.06.012.
10. Pande A, Sharma S, Khillan V, Rastogi A, Arora V, Shasthry SM, et al. Fecal microbiota transplantation compared with prednisolone in severe alcoholic hepatitis patients: a randomized trial. Hepatol Int. 2023;17(1):249-261. doi:10.1007/s12072-022-10438-0.
11. Sharma A, Roy A, Premkumar M, Verma N, Duseja A, Taneja S, et al. Fecal microbiota transplantation in alcohol-associated acute-on-chronic liver failure: an open-label clinical trial. Hepatol Int. 2022;16(2):433-446. doi:10.1007/s12072-022-10312-z.
12. Mishra AK, Goel A. Stratification and selection of therapies to improve survival in severe alcoholic hepatitis. World J Hepatol. 2025;17(9):109118. doi:10.4254/wjh.v17.i9.109118.
13. Kulkarni AV, Premkumar M, Kumar K, Roy A, Giri S, Pasumarthy A, et al. Recompensation in Patients With Alcohol-Related Liver Disease-A Multicenter Study. Gastro Hep Adv. 2026;5(5):100897. doi:10.1016/j.gastha.2026.100897.
14. Philips CA. A comprehensive review of diagnosis and management of alcohol-associated hepatitis. SAGE Open Med. 2024;12:20503121241297000. doi:10.1177/20503121241297000.
15. Badi S, et al. Clinical Spectrum, Etiology, and Complications of Liver Cirrhosis at a Tertiary Care Center in Western India: An Observational Clinic-Based Cohort Study. Cureus. 2025;17(11):e97022. doi:10.7759/cureus.97022.
16. Noklang S, Noklang I, Chirumamilla SSK, Kannauje PK. Serum uric acid level in chronic liver disease and its correlation with Child-Pugh score in a tertiary care hospital from South India. J Family Med Prim Care. 2023;12(11):2696-2701. doi:10.4103/jfmpc.jfmpc_847_23.
17. Bharath CS, Chatterjee K, Yadav AS, Dangi A, Bhat PS. Alcohol dependence syndrome in patients with alcoholic liver disease: A cross sectional observational study. Ind Psychiatry J. 2024;33(Suppl 1):S142-S147. doi:10.4103/ipj.ipj_222_22.
18. Kumar A, Arora A, Choudhury A, Arora V, Rela M, Jothimani DK, et al. Diabetes mellitus is linked to higher mortality in alcohol-related acute-on-chronic liver failure. Hepatol Int. 2026;20(1):149-162. doi:10.1007/s12072-025-10914-3.
19. Murthy P, Shadakshari D, Mahadevan J, Chand PK. Management of Alcohol Use Disorder in Patients With Alcoholic Liver Disease. J Clin Exp Hepatol. 2022;12(6):1514-1526. doi:10.1016/j.jceh.2022.04.010.
20. Patel R, Mueller M. Alcohol-Associated Liver Disease. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. PMID: 31536239.
21. Sah AK, et al. Innovative Strategies in the Diagnosis and Treatment of Liver Cirrhosis. Life (Basel). 2025;15(5):779. doi:10.3390/life15050779.
22. Sharma S, Agarwal S, Saraya A, Choudhury A, Mahtab MA, Alam MS, et al. Acute variceal bleeding portends poor outcomes in patients with acute-on-chronic liver failure: a propensity score matched study from the APASL ACLF Research Consortium (AARC). Hepatol Int. 2022;16(5):1234-1243. doi:10.1007/s12072-022-10372-1.
23. Singh S, Taneja S, Roy A, Rathi S, De A, Verma N, et al. Simple bedside tests of muscle strength and function correlate with computed tomography-skeletal muscle index for assessment of sarcopenia in cirrhosis. Indian J Gastroenterol. 2023;42(3):379-387. doi:10.1007/s12664-023-01338-8.
24. Singh S, Taneja S, Tandon P, Bansal A, Gorsi U, Roy A, et al. A Comparison of Different Frailty Scores and Impact of Frailty on Outcome in Patients With Cirrhosis. J Clin Exp Hepatol. 2022;12(2):398-408. doi:10.1016/j.jceh.2021.07.003.
25. Maheshwari S, Gu CN, Caserta MP, Kezer CA, Shah VH, Torbenson MS, et al. Imaging of Alcohol-Associated Liver Disease. AJR Am J Roentgenol. 2024;222(1):e2329917. doi:10.2214/AJR.23.29917.

26. Nelaturi P, Kademani SP, Siva Subramanian V, Ravikumar S. Noninvasive Biomarkers for Alcohol-Related Liver Disease—A Proteomic Related Preliminary Report. Indian J Clin Biochem. 2024;39(3):392-400. doi:10.1007/s12291-023-01120-9.
27. Lavichan L, et al. Serum Magnesium Levels Across Clinical Stages of Alcoholic Liver Disease: A Cross-Sectional Study From South India. Cureus. 2026;18(6):e110388. doi:10.7759/cureus.110388.
28. Ghare SS, Charpentier BT, Ghooray DT, Zhang J, Vadhanam MV, Reddy S, et al. Tributyrin Mitigates Ethanol-Induced Lysine Acetylation of Histone-H3 and p65-NFκB Downregulating CCL2 Expression and Consequent Liver Inflammation and Injury. Nutrients. 2023;15(20):4397. doi:10.3390/nu15204397.
29. Philips CA, Ahamed R, Rajesh S, Abduljaleel JKP, Augustine P. Long-term Outcomes of Stool Transplant in Alcohol-associated Hepatitis—Analysis of Clinical Outcomes, Relapse, Gut Microbiota and Comparisons with Standard Care. J Clin Exp Hepatol. 2022;12(4):1124-1132. doi:10.1016/j.jceh.2022.01.001.
30. Joshi B, Challa U, Aayush, Hernandez R, Devkota K, Yadav P, et al. Prevalence, Clinical Profiles, Disease Severity, and Patient Outcomes of Alcoholic Liver Disease in a Tertiary Care Hospital of Nepal. Health Sci Rep. 2026;9(6):e72499. doi:10.1002/hsr2.72499.

Copyright & License:
© Authors retain the copyright of this article. This work is published under the Creative Commons Attribution 4.0 International License (CC BY 4.0), permitting unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.